Wednesday, October 23, 2024
spot_img

PayPoint plc : Director/PDMR Shareholding

23 October 2024

PayPoint plc (“the Company”)

Notifications of transactions by Persons Discharging Managerial Responsibilities

(together “PDMRs”)

The PayPoint plc Share Incentive Plan

This announcement includes details in respect of the monthly acquisition of Partnership Shares and award of Matching Shares under the PayPoint plc Share Incentive Plan (“SIP”) made on 22 October 2024, in respect of those PDMRs who are participants in the SIP, as set out below, including the following Executive Directors:

PDMR Partnership Shares Purchased

Award Date: 22/10/2024

Purchase Price: £7.459

Matching Shares

Award Date: 22/10/2024

Allotment Price: £0.00333

Nicholas Wiles 17 17
Rob Harding 17 17

        
The Notification of Dealing Forms can be found below.

This Notification is made in accordance with the requirements of the UK Market Abuse Regulation.

ENQUIRIES:        
PayPoint plc           

Julia Herd, on behalf of Indigo Corporate Secretary Limited, Company Secretary
+44 (0)7542 031173

Steve O’Neill, Chief Marketing and Corporate Affairs Officer
+44 (0)7919 488066

LEI: 5493004YKWI8U0GDD138

http://corporate.paypoint.com/

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name 1. Simon Coles
2. Benjamin Ford
3. Rob Harding
4. Mark Latham
5. Tanya Murphy
6. Stephen O’Neill
7. Christopher Paul
8. Anthony Sappor
9. Josephine Toolan
10. Katy Wilde
11. Nicholas Wiles
12. Nicholas Williams
2 Reason for the notification
a) Position/status
  1. PDMR
  2. PDMR
  3. Chief Financial Officer
  4. PDMR
  5. PDMR
  6. PDMR
  7. PDMR
  8. PDMR
  9. PDMR
  10. PDMR
  11. Chief Executive
  12. PDMR
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name PayPoint plc
b) LEI 5493004YKWI8U0GDD138
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1/3 pence

ISIN: GB00B02QND93

b) Nature of the transaction Shares purchased pursuant to the PayPoint plc Share Incentive Plan.

c) Price(s) and volume(s)   Price(s) Volume(s)
1. £7.459 16
2. £7.459 17
3. £7.459 17
4. £7.459 17
5. £7.459 16
6. £7.459 17
7. £7.459 17
8. £7.459 16
9. £7.459 17
10. £7.459 16
11. £7.459 17
12. £7.459 14
d) Aggregated information

– Volume
– Price
– Total

  Aggregate Volume(s) Aggregate Price(s) Aggregate Total
1. 16 £7.459 £119.34
2. 17 £7.459 £126.80
3. 17 £7.459 £126.80
4. 17 £7.459 £126.80
5. 16 £7.459 £119.34
6. 17 £7.459 £126.80
7. 17 £7.459 £126.80
8. 16 £7.459 £119.34
9. 17 £7.459 £126.80
10. 16 £7.459 £119.34
11. 17 £7.459 £126.80
12. 14 £7.459 £104.42
e) Date of the transaction 22 October 2024
f) Place of the transaction XLON

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name 1. Simon Coles
2. Benjamin Ford
3. Rob Harding
4. Mark Latham
5. Tanya Murphy
6. Stephen O’Neill
7. Christopher Paul
8. Anthony Sappor
9. Josephine Toolan
10. Katy Wilde
11. Nicholas Wiles
12. Nicholas Williams
2 Reason for the notification
a) Position/status
  1. PDMR
  2. PDMR
  3. Chief Financial Officer
  4. PDMR
  5. PDMR
  6. PDMR
  7. PDMR
  8. PDMR
  9. PDMR
  10. PDMR
  11. Chief Executive
  12. PDMR
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name PayPoint Plc
b) LEI 5493004YKWI8U0GDD138
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1/3 pence

ISIN: GB00B02QND93

b) Nature of the transaction Matching shares issued pursuant to the PayPoint plc Share Incentive Plan.
c) Price(s) and volume(s)   Price(s) Volume(s)
1. £0.00333 16
2. £0.00333 17
3. £0.00333 17
4. £0.00333 17
5. £0.00333 16
6. £0.00333 17
7. £0.00333 17
8. £0.00333 16
9. £0.00333 17
10. £0.00333 16
11. £0.00333 17
12. £0.00333 14
d) Aggregated information

– Volume
– Price
– Total

  Aggregate Volume(s) Aggregate Price(s) Aggregate Total
1. 16 £0.00333 £0.05
2. 17 £0.00333 £0.06
3. 17 £0.00333 £0.06
4. 17 £0.00333 £0.06
5. 16 £0.00333 £0.05
6. 17 £0.00333 £0.06
7. 17 £0.00333 £0.06
8. 16 £0.00333 £0.05
9. 17 £0.00333 £0.06
10. 16 £0.00333 £0.05
11. 17 £0.00333 £0.06
12. 14 £0.00333 £0.05
e) Date of the transaction 22 October 2024
f) Place of the transaction Outside of a trading venue

Powered by SlickText.com

Hot this week

Alliance Witan PLC – Transaction In Own Shares

Alliance Witan PLCLEI: 213800SZZD4E2IOZ9W55  TRANSACTION IN OWN SHARES  Alliance Witan...

Weekly share repurchase program transaction details

October 23, 2024 SBM Offshore reports the transaction...

Transaction in Own Shares

Transaction in Own Shares 23 October, 2024 ...

Umicore – Transparency notifications by BlackRock, Inc. and by Bank of America Corp.

Transparency notifications by BlackRock, Inc. and by Bank of...

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

DARE-HPV is a potential first-in-category treatment for human papillomavirus...

Topics

Alliance Witan PLC – Transaction In Own Shares

Alliance Witan PLCLEI: 213800SZZD4E2IOZ9W55  TRANSACTION IN OWN SHARES  Alliance Witan...

Weekly share repurchase program transaction details

October 23, 2024 SBM Offshore reports the transaction...

Transaction in Own Shares

Transaction in Own Shares 23 October, 2024 ...

Umicore – Transparency notifications by BlackRock, Inc. and by Bank of America Corp.

Transparency notifications by BlackRock, Inc. and by Bank of...

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

DARE-HPV is a potential first-in-category treatment for human papillomavirus...

SYNERGIE : Q3 2024 REVENUES

Q3 2024 REVENUES In challenging market conditions, SYNERGIE...

2024 third quarter turnover: 131.1 million euros

2024 third quarter turnover: 131.1 million euros ...
spot_img

Related Articles

Popular Categories

spot_img